The invention relates to the use of compounds of formula (I), wherein ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which optionally may contain 1-3 heteroatoms selected independently from O, N and S; Z is -O-, -NH-, -S-, -CH2- or a direct bond; n is 0-5; m is 0-3; R2 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C?1-3?alkyl, C1-3alkoxy, C1-3alkylsulphanyl, -NR?3R4? (wherein R?3 and R4?, which may be the same or different, each represents hydrogen or C?1-3?alkyl), or R?5X1?- (wherein X?1 and R5? are as defined herein; R1 represents hydrogen, oxo, halogeno, hydroxy, C?1-4?alkoxy, C1-4alkyl, C1-4alkoxymethyl, C1-4alkanoyl, C1-4haloalkyl, cyano, amino, C2-5alkenyl, C2-5alkynyl, C1-3alkanoyloxy, nitro, C1-4alkanoylamino, C1-4alkoxycarbonyl, C1-4alkylsulphanyl, C1-4alkylsulphinyl, C1-4alkylsulphonyl, carbamoyl, N-C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, aminosulphonyl, N-C1-4alkylaminosulphonyl, N,N-di(C1-4alkyl)aminosulphonyl, N-(C1-4alkylsulphonyl)amino, N-(C1-4alkylsulphonyl)-N-(C1-4alkyl)amino, N,N-di(C1-4alkylsulphonyl)amino, a C3-7alkylene chain joined to two ring C carbon atoms, C1-4alkanoylaminoC1-4alkyl, carboxy or a group R?56X10? (wherein X?10 and R56? are as defined herein); and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula (I). The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

Quinazoline derivatives as angiogenesis inhibitors

This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

Ophthalmic compositions for treating ocular hypertension

Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.

Ppar active compounds

Compounds of general formula (I) wherein R is phenyl optionally substituted with one or more halo substituents; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

Compounds having CRTH2 antagonist activity

The invention concerns the use of a compound of formula (I), and their pharmaceutically acceptable salts or in vivo hydrolysable esters, in the treatment of a disease or condition mediated by monocyte chemoattractant protein-1 (MCP-1). Certain of the components of formula (I) are novel and are provided, together with pharmaceutical compositions thereof, as further features of the invention.

Indole derivatives and their use as mcp-1 antagonists

NEW 3-SUBSTITUTED-1 - INDOLE- AND 4,5,6,7 - TETRAHYDROINDOLE-LOWER-ALKANOIC ACIDS AND ESTERS HAVING USEFUL ANTIINFLAMMATORY ACTIVITY AND PREPARED BY ALKYLATION OF A 3 - SUBSTITUTED - INDOLE WITH AN APPROPRIATE HALO-LOWER-ALKANOIC ACID OR ESTER OR BY CYCLIZATION OF A 2-(2-R2-2-OXOETHYL) CYCLOHEXANONE OR 2-(1 -PHENYL-2-OXO-LOWER-ALKYL) CYCLOHEXANONE WITH AN AMINO ACID OR ESTER.

4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters

New 3-substituted-1-indole-lower-alkanoic acids and esters having useful anti-inflammatory activity and prepared by alkylation of a 3-substituted-indole with an appropriate halolower-alkanoic acid or ester.

Bell M

Papers

4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters

Alpha-(3-(4-chlorobenzoyl)-2-methyl-6-methoxy-1-ndole)-acetic acid

Indolderivate und Verfahren zu ihrer Herstellung